CANF
Can-Fite BioPharma Ltd.$3.07
LiveJun 18, 2026
Market cap
$1.65M
52w range
2.82 – 21.80
P / E
—
EPS
—
Volume
7.44K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Can-Fite BioPharma Ltd.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $5.00 (+62.87%)
Candlestick · 1Y
Open in chart workstation →CANF
2.99-27.60%H 10.40L 2.82MA50 3.41MA200 —Avg vol 618K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.32% | +5.50% | -5.83% | -10.76% | -38.60% | -23.25% | -85.52% | -95.29% | -99.33% | -99.96% | -99.98% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$3.07
1 sh
Bid
$3.00
61 sh
Ask
$3.07
4 sh
Spread
$0.070
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.53%
- Communication Services+2.28%
- Utilities+0.64%
- Consumer Cyclical+0.47%
- Consumer Defensive-0.32%
- Industrials-0.48%
- Basic Materials-0.64%
- Energy-0.75%
- Real Estate-0.76%
- Financial Services-1.08%
- Healthcare-1.31%
Top industries (issuer's industry highlighted)
- Biotechnology-4.85%
- Business Equipment & Supplies+6.57%
- Electronic Gaming & Multimedia+6.45%
- Other Precious Metals-4.95%
- Semiconductors+4.52%
- Medical - Equipment & Services+4.26%
- Grocery Stores-4.13%
- Oil & Gas Drilling-3.68%
- Internet Content & Information+3.47%
- Financial - Mortgages+3.40%
- Gold-3.28%
- Oil & Gas Equipment & Services-3.15%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapyglobenewswire.com·May 13, 2026
- Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapyglobenewswire.com·May 13, 2026
Peers
No peer list available for CANF.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|